paromomycin

paromomycin C화학적 특성, 용도, 생산

개요

Paromomycin is recommended for treatment of acute and chronic forms of intestinal amobiasis, as well as for treating intestinal bacteria Salmonella and Shigella. Synonyms of this drug are aminosidine, catenulin, crestomycin, hydroxymycin, monomycin, zygomycyn, and others.

Indications

The antibacterial activity and indications for using paromomycin are analogous to those of neomycin. In addition, it is recommended for treating severe and chronic forms of gastric amebiasis. Synonyms of this drug are aminosidine, catenulin, crestomycin, hydroxymycin, monomycin, zygomycyn, and others.

World Health Organization (WHO)

Paromomycin, an aminoglycoside antibiotic was introduced into medicine in 1959 for the treatment of protozoal, helminthic and bacterial infections. It has been associated, particularly when used by parenteral route, with severe adverse effects including renal damage, neuromuscular blockage and ototoxicity, possibly leading to deafness in some patients. This route of administration is now considered obsolete. However, parenteral dosage forms of paromomycin may still remain available in certain countries.

Antimicrobial activity

A fermentation product of Streptomyces rimosus var. paromomycinus, supplied as the sulfate. The commercial product is a mixture of the two isomeric paromomycins I and II, which are closely related to neomycin.
The antibacterial activity is almost identical to that of neomycin. Since it differs from neomycin in having a hydroxyl rather than an amino group at the 6′-position it is not sensitive to AAC(6′) modifying enzymes. It is active against M. tuberculosis, including multidrug-resistant strains, and the M. avium complex.
Unlike other aminoglycosides, paromomycin is active against some protozoa, including Entamoeba histolytica, Cryptosporidium parvum, Leishmania spp., Giardia lamblia and Trichomonas vaginalis. It also exhibits activity against the tapeworms Taenia saginata, Taenia solium, Diphyllobothrium latum and Hymenolepis nana.
It closely resembles neomycin in pharmacokinetic behavior and liability to produce deafness and intestinal malabsorption.

Clinical Use

Intestinal amebiasis (oral)
Cutaneous leishmaniasis (topical) and visceral leishmaniasis (intramuscular)
Nitroimidazole-resistant trichomoniasis (topical)
Its antiprotozoal activity has attracted some attention, but it has largely been superseded by more active and less toxic compounds. Success in treating nitroimidazole-resistant trichomoniasis with topical paromomycin has been reported. Trials in India and East Africa of parenteral paromomycin alone, or in combination with sodium stibogluconate, for treatment of visceral leishmaniasis have shown promising results.

paromomycin 준비 용품 및 원자재

원자재

준비 용품

paromomycin 공급 업체

공급자	전화	이메일	국가	제품 수	이점
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
career henan chemical co	+86-0371-86658258 15093356674;	factory@coreychem.com	China	29826	58
AFINE CHEMICALS LIMITED	0571-85134551	info@afinechem.com	CHINA	15377	58
Dayang Chem (Hangzhou) Co.,Ltd.	571-88938639 +8617705817739	info@dycnchem.com	CHINA	52867	58
PT CHEM GROUP LIMITED	+86-85511178 +86-85511178	peter68@ptchemgroup.com	China	35453	58
GIHI CHEMICALS CO.,LIMITED	+8618058761490	info@gihichemicals.com	China	50000	58
China National Standard Pharmaceutical Corporation Limited	+8615391658522	overseasales@yongstandards.com	China	11927	58
GIHI CHEMICALS CO.,LIMITED	08657186217390	sales@gihichemicals.com	CHINA	309	58
Gihi Chemicals Co., Limited	+86-0571-86217390 +8618058761490	info@gihichem.com	China	998	58
Beijing HuaMeiHuLiBiological Chemical	010-56205725	waley188@sohu.com	China	12338	58

paromomycin 관련 검색: